Patients with chronic migraine and medication overuse had significantly different FAAH gene expression compared to episodic migraine patients, and these differences correlated with headache severity and psychiatric symptoms.
People interested in the endocannabinoid system's role in migraine and chronic pain, and researchers exploring biomarkers for headache disorders.
FAAH gene expression 4x lower in chronic vs episodic migraine
What the researchers found
FAAH (fatty acid amide hydrolase), the enzyme that breaks down the endocannabinoid anandamide, showed significantly lower gene expression in medication overuse headache (MOH) patients compared to episodic migraine (EM) patients. Paradoxically, FAAH protein levels were higher in MOH patients. Lower FAAH gene expression correlated with worse headache impact scores (HIT-6), disability scores (MIDAS), and higher scores on anxiety, depression, and alexithymia scales.
Why it matters
The endocannabinoid system is a key regulator of pain, and FAAH is the enzyme that determines how long endocannabinoids remain active. Finding that FAAH is specifically altered in chronic migraine patients suggests the endocannabinoid system may be dysregulated in headache chronification, potentially explaining why some migraine patients report benefit from cannabis.
The numbers in context
31 patients + 14 healthy controls. FAAH gene expression: MOH 0.0002 vs EM 0.0008 (p=0.005). FAAH protein: MOH 2.95 pg/ug vs EM 0.92 pg/ug (p=0.025). Negative correlations with HIT-6 (p=0.003), MIDAS (p=0.048), TAS-20 (p=0.029), HAM-A (p=0.040), HAM-D (p=0.028).
How the study worked
Cross-sectional study of 31 patients (15 episodic migraine, 16 medication overuse headache) and 14 healthy controls. FAAH was measured via ELISA (protein) and real-time quantitative PCR (gene expression) in peripheral blood mononuclear cells. Seven additional ECS components were also assessed. Clinical and psychopathological scales administered.
What this study cannot tell us
Very small sample size (31 patients, 14 controls). Cross-sectional design; cannot determine if FAAH changes cause or result from chronic migraine. Peripheral blood measurements may not reflect brain endocannabinoid levels. No cannabinoid receptor gene expression differences found between groups.
How to read the evidence
Preliminary: very small sample, cross-sectional design, and single-center recruitment.
When this study was published
Published in 2025.
The bigger picture
FAAH inhibitors have been explored as potential therapeutics for pain and anxiety. This study suggests FAAH dysregulation may be a biomarker that distinguishes chronic migraine from episodic migraine, potentially opening a path toward endocannabinoid-based treatments for headache disorders.
Questions still open
- Could FAAH levels serve as a blood biomarker for migraine chronification?
- Would FAAH inhibitors help prevent medication overuse headache?
- Does the FAAH gene-protein discrepancy reflect a compensatory mechanism?
Common questions
Is the endocannabinoid system involved in migraines?
Could endocannabinoid-based treatments help with chronic migraine?
Read the original research
Genetic characterization of the endocannabinoid system and psychiatric features in patients with migraine and medication overuse headache.
Cephalalgia : an international journal of headache, 45(7), 3331024251314460
Citation
Romozzi, Marina; Scipioni, Lucia; Di Tella, Sonia; Silveri, Maria Caterina; Cupini, Letizia Maria; Vollono, Catello; Maccarrone, Mauro; Calabresi, Paolo. (2025). Genetic characterization of the endocannabinoid system and psychiatric features in patients with migraine and medication overuse headache.. Cephalalgia : an international journal of headache, 45(7), 3331024251314460. https://doi.org/10.1177/03331024251314460
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)